In our huPBMC‐NOG‐PDX model, targeting RIME significantly inhibited tumour development and showed a better antitumour effect than PD‐1 mAb monotherapy (Figure 5I and Figure S5L). This evidence concerns the gene PDCD1 and neoplasm.